Related Experiment Video
Updated: Aug 21, 2026
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
Cripto expression in human urological tumors
E Okajima1, M Tsutsumi, E Okajima
1Department of Oncological Pathology, Cancer Center, Nara Medical University, Shijyo-cho, Kashihara, Japan.
Abstract:
The expression of cripto, a novel transforming gene of the epidermal growth factor superfamily, was immunohistochemically examined in 20 cases of urinary bladder, one ureter, three renal pelvic, 18 kidney, nine prostate, three adrenal and four testicular tumors. Three cases of urinary bladder carcinomas, two of grade 2 and one of grade 3 transitional cell carcinoma which were T1a and T3b, and INF beta and INF gamma, respectively, showed positive binding of specific antibody, along with one cortical carcinoma of the adrenal gland positive staining. None of the ureter, renal pelvic, kidney, prostate or testicular tumors showed positive staining. These results indicate that cripto is not frequently expressed in urological tumors.
Insights
Cripto gene expression was investigated in various urological tumors. This study found limited cripto expression in bladder and adrenal cancers, suggesting it is not common in these cancers.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Cripto is a transforming gene within the epidermal growth factor superfamily.
- Understanding gene expression in tumors is crucial for diagnosis and treatment.
Purpose of the Study:
- To examine the expression of the cripto gene in a variety of urological tumors.
- To determine the prevalence of cripto expression in different types of urological malignancies.
Main Methods:
- Immunohistochemical analysis was employed to detect cripto expression.
- The study analyzed tumor samples from urinary bladder, ureter, renal pelvis, kidney, prostate, adrenal gland, and testes.
Main Results:
- Positive cripto staining was observed in three cases of urinary bladder transitional cell carcinoma (two grade 2, one grade 3) and one adrenal cortical carcinoma.
- No cripto expression was detected in tumors of the ureter, renal pelvis, kidney, prostate, or testes.
Conclusions:
- Cripto expression is infrequent in the analyzed urological tumors.
- The findings suggest cripto is not a common biomarker in most urological cancers.
